Home › Open-Angle Glaucoma › NCT07816692

iDose TR Administration in an Office-Based Surgery Setting

Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion Criteria:

* Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation

About the study

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

What is being tested

• iDose TR (travoprost intracameral implant) 75 µg (combination product)

Sponsor: Glaukos Corporation · Participants: 30 · Started: May 13, 2026

Contact the study team

• Study Director · Phone: 949-739-8749

Official record on ClinicalTrials.gov — NCT07816692

Locations in the U.S.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension
• Glaucoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.